Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Barnes
C
C
Davis
A
A
Furmedge
J
J
Egan
B
B
Donnan
L
L
Monagle
P
P
D000707:Anaphylaxis / Q000139:chemically induced / Q000517:prevention & control*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D019774:Blood Coagulation Factor Inhibitors; D002648:Child; D003888:Desensitization, Immunologic / Q000379:methods*; D005164:Factor IX / Q000009:adverse effects; D002836:Hemophilia B / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000502:physiology; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D019774:Blood Coagulation Factor Inhibitors; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab; D005164:Factor IX